Researcher Portfolio

 
   

Nocentini, Riccardo

ITER Technology & Diagnostics (ITED), Max Planck Institute for Plasma Physics, Max Planck Society, Technology (TE), Max Planck Institute for Plasma Physics, Max Planck Society, Tokamak Scenario Development (E1), Max Planck Institute for Plasma Physics, Max Planck Society  

 

Researcher Profile

 
Position: Technology (TE), Max Planck Institute for Plasma Physics, Max Planck Society
Position: ITER Technology & Diagnostics (ITED), Max Planck Institute for Plasma Physics, Max Planck Society
Position: Tokamak Scenario Development (E1), Max Planck Institute for Plasma Physics, Max Planck Society
Researcher ID: https://pure.mpg.de/cone/persons/resource/persons110064

External references

 

Publications

 
 
 : Camacho-Carvajal, M. M., Wollscheid, B., Aebersold, R., Steimle, V., & Schamel, W. W. A. (2004). Two-dimensional Blue Native/SDS Gel Electrophoresis of Multi-Protein Complexes from Whole Cellular Lysates. Molecular & Cellular Proteomics, 3, 176-182. [PubMan] : Camacho-Carvajal, M. M., Klingler, S., Schnappauf, F., Hake, S. B., & Steimle, V. (2004). Importance of class II transactivator leucine-rich repeats for dominant-negative function and nucleo-cytoplasmic transport. International Immunology, 16(1), 65-75. [PubMan] : Ehlers, M., Laule-Kilian, K., Petter, M., Aldrian, C. J., Grueter, B., Würch, A., Yoshida, N., Watanabe, T., Satake, M., & Steimle, V. (2003). Morpholino Antisense Oligonucleotide-Mediated Gene Knockdown During Thymocyte Development Reveals Role for Runx3 Transcription Factor in CD4 Silencing During Development of CD4-/CD8+ Thymocytes. Journal of Immunology, 171(7), 3594-3604. [PubMan] : Hake, S. B., Tobin, H. M., Steimle, V., & Denzin, L. K. (2003). Comparison of the transcriptional regulation of classical and non-classical MHC class II genes. European Journal of Immunology, 33(9), 2361-2371. [PubMan] : Schnappauf, F., Hake, S. B., Camacho Carvajal, M. M., Bontron, S., Lisowska-Grospierre, B., & Steimle, V. (2003). N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. European Journal of Immunology, 33(8), 2337-2347. [PubMan] : Otten, L. A., Tacchini-Cottier, F., Lohoff, M., Annunziato, F., Cosmi, L., Scarpellino, L., Louis, J., Steimle, V., Reith, W., & Acha-Orbea, H. (2003). Deregulated MHC Class II Transactivator Expression Leads to a Strong Th2 Bias in CD4 T Lymphocytes. Journal of Immunology, 170(3), 1150-1157. [PubMan] : Dziembowska, M., Fondaneche, M.-C., Vedrenne, J., Barbieri, G., Wiszniewski, W., Picard, C., Cant, A. J., Steimle, V., Charron, D., Alca-Loridan, C., Fischer, A., & Lisowska-Grospierre, B. (2002). Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency. Immunogenetics, 53(10-11), 821-829. [PubMan]